



*To Improve the Lives of Patients by
Creating and Developing Innovative*

Antibody Products

www.genmab.com

Scientific Articles

Ofatumumab

Czuczman, M.S., L. Fayad, V. Delwail, G. Carton, E. Jacobsen, K. Kullickowski, B.K. Link, L. Pinter-Brown, J. Radford, A. Hellmann, E. Gallop-Evans, C.G. DiRienzo, N. Goldstein, I. Gupta, R.C. Jewell, T.S. Lin, S. Lisby, M. Schultz, C.A. Russel, A. Hagenbeek. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from multicenter study. **Blood**. 2012; 119(16): 3698-3704.

Czuczman, M.S., G. Hess, O.V. Gadeberg, L.M. Pedersen, N. Golstein, I. Gupta, R.C. Jewell, T.S. Lin, S. Lisby, C. Strange, K. Windfeld, A. Viardot. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. **British Journal of Haematology**. 2012; 157(4): 438-445.

Beurskens, F.J., M.A. Lindorfer, M. Farooqui, P.V. Beum, P. Engelberts, W.J.M. Mackus, P.W.H.I. Parren, A. Wiestner, R.P. Taylor. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. **The Journal of Immunology**. 2012; 188(7): 3532-3541.

Baig, N.A., R.P. Taylor, M.A. Lindorfer, A.K. Church, B.R. Laplant, E.S. Pavey, G.S. Nowakowski, C.S. Zent. Complement dependent cytotoxicity (CDC) in chronic lymphocytic leukemia (CLL): Ofatumumab enhances alemtuzumab CDC and reveals cells resistant to activated complement. **Leukemia and Lymphoma**. 2012; 53(11): 2218-2227.

Barth, M.J., F.J. Hernandez-Ilizaliturri, C. Mavis, P.C. Tsai, J.F. Gibbs, G. Deeb, M.S. Czuczman. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. **Br J Haematol**. 2012 Feb;156(4):490-8.

Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, Leusen JH. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. **Hematologica**. 2011 Dec;96(12):1822-30.

Beum, P.V., M.A. Lindorfer, E.M. Peek, P. T. Stukenberg, M. de Weers, F.J. Beurskens, P.W.H.I. Parren, J.G.J. van de Winkel, and R.P. Taylor. Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes calcium influx and induces streamers. **Eur. J. Immunol**. 2011; 41: 2436-2446.

Beum, P.V., E.M. peek, M.A. Lindorfer, F.J. Beurskens, P.J. Engelberts, P.W.H.I. Paren, J.G.J. van de Winkel, and R.P. Taylor. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. **J. Immunol**. 2011; 187: 3438-3447.

Taylor, P.C., E. Quattrocchi, S. Mallett, R. Kurrasch, J. Petersen, and D.J. Chang. Ofatumumab, a fully human anti-CD20 mAb, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. **Ann Rheum Dis**. 2011; 70: 2119-2125.

Wierda, W.G., S. Padmanabhan, G.W. Chan, I.V. Gupta, S. Lisby, and A. Osterborg. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from ph II international study. **Blood** 2011; 118: 5126-5129.

Wierda, W.G., T.J. Kipps, J. Dürig, L. Griskevicius, S. Stilgenbauer, J. Mayer, L. Smolej, G. Hess, R. Griniute, F.J. Hernandez-Ilizaliturri, S. Padmanabhan, M. Gorczyca, C.N. Chang, G. Chan, I. Gupta, T.G. Nielsen, and C.A. Russell; 407 Study Investigators. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. **Blood**. 2011; 117: 6450-6458.

De Haij, S., J.H.M. Jansen, P. Boross, F.J. Beurskens, J.E. Bakema, D.L. Bos, A. Martens, J.S. Verbeek, P.W.H.I. Parren, J.G.J. van de Winkel, and J.H.W. Leusen. In vivo cytotoxicity of type I CD20 antibodies critically depends on FcR ITAM signaling. **Cancer Res**. 2010; 70: 3209-3217.

Kap, Y.S., N. van Driel, E. Blezer, P.W.H.I. Parren, W.K. Bleeker, J.D. Laman, J.L. Craigen, and B.A. 't Hart. Late B Cell Depletion with a Human Anti-Human CD20 IgG1{ κ } Monoclonal Antibody Halts the Development of Experimental Autoimmune Encephalomyelitis in Marmosets. **J. Immunol**. 2010; 185:3990-4003.

Østergaard, M., B. Baslund, W. Rigby, B. Rojkovich, C. Jorgensen, P.T. Dawes, C. Wiell, D.J. Wallace, S.C. Tamer, H. Kastberg, J. Petersen, and S. Sierakowski. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. **Arthritis Rheum**. 2010; 62: 2227-2238.

Coiffier, B, N. Losic, B.B. Rønn, S. Lepretre, L.M. Pedersen, O. Gadeberg, H. Frederiksen, M.H. van Oers, J. Wooldridge, J. Kloczko, J. Holowiecki, A. Hellmann, J. Walewski, T. Robak, J. Petersen. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. **Br. J. Haematol**. 2010;150: 58-71.

Wierda, WG, T.J. Kipps, J. Mayer, S. Stilgenbauer, C.D. Williams, A. Hellmann, T. Robak, R.R. Furman, P. Hillmen, M. Trneny, M.J. Dyer, S. Padmanabhan, M. Piotrowska, T. Kozak, G. Chan, R. Davis, N. Losic, J. Wilms, C.A. Russell, and A. Osterborg. Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. **J. Clin. Oncol**. 2010; 28: 1749-1755.

Pawluczko, A., F.J. Beurskens, P.V. Beum, M.A. Lindorfer, J.G.J. van de Winkel, P.W.H.I. Parren, and R.P. Taylor. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): Considerably higher levels of CDC are induced by OFA than by RTX. **J. Immunol**. 2009; 183: 749-758.

Beurskens, F.J., S.R. Ruuls, P.J. Engelberts, T. Vink, W.J. Mackus, J.G.J. van de Winkel, and P.W.H.I. Parren. Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies. **Blood** 2008; 112: 4354-4355.
Beum P.V., M.A. Lindorfer, F. Beurskens, P.T. Stukenberg, P.W.H.I. Parren, J.G.J. van de Winkel, and R.P. Taylor. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. **J. Immunol**. 2008; 181: 822-832.

Hagenbeek A., O. Gadeberg, P. Johnson, L.M. Pedersen, J. Walewski, A. Hellmann, B.K. Link, T. Robak, M. Wojtukiewicz, M. Pfreundschuh, M. Kneba, A. Engert, P. Sonneveld, M. Flensburg, J. Petersen, N. Losic, J. Radford. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. **Blood** 2008; 111: 5486-5495.

Wijngaarden, S., J.G.J. van de Winkel, J.W.J. Bijlsma, F.P.J.G. Lafeber, and J.A.G. van Roon. Treatment of rheumatoid arthritis patients with anti-TNF- α monoclonal antibody is accompanied by down-regulation of activating Fc γ Receptor I on monocytes. **Clin. Exp. Rheumatol**. 2008; 26: 89-95.

Winiarska, M., J. Bil, E. Wilczek, G.M. Wilczynski, M. Lekka, P.J. Engelberts, W.J.M. Mackus, E. Gorska, L. Bojarski, T. Stoklosa, D. Nowis, Z. Kurzaj, M. Makowski, E. Glodkowska, T. Issat, P. Mrowka, W. Lasek, A. Dabrowska-Iwanicka, G.W. Basak, M. Wasik, K. Warzocha, M. Sinski, Z. Gaciong, M. Jakobisiak, P.W.H.I. Parren, and J. Golab. Statins impair antitumor effects of Rituximab by inducing conformational changes of CD20. **PLoS Medicine** 2008; 5: e64.

Bleeker, W.K., M.E. Munk, W.J.M. Mackus, J.H.N. van den Brakel, M. Pluyter, M.J. Glennie, J.G.J. van de Winkel, and P.W.H.I. Parren. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. **Brit. J. Haematol**. 2008; 140: 303-312.

Ofatumumab Continued

Coiffier, B., S. Lepetre, L.M. Pedersen, O. Gadeberg, H. Fredriksen, M.H. van Oers, J. Wooldridge, J. Kloczko, J. Holowiecki, A. Hellmann, J. Walewski, M. Flensburg, J. Pedersen and T. Robak. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. **Blood** 2008; 111: 1094-1100.

Teeling, J., W.J.M. Mackus, L.J.J.M. Wiegman, J.H.N. van den Brakel, S.A. Beers, R.R. French, T. van Meerten, S. Ebeling, T. Vink, J.W. Slootstra, P.W.H.I. Parren, M.J. Glennie, and J.G.J. van de Winkel. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. **J. Immunol.** 2006; 177: 362-371.

Teeling, J.L., R.R. French, M.S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P.W.H.I. Parren, C.E. Hack, M. Dechant, T. Valerius, J.G.J. van de Winkel and M.J. Glennie. Characterisation of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. **Blood** 2004; 104 : 1793-1800.

Daratumumab

Groen, R.W.J., R.A. Raymakers, H.J. Prins, L. Aalders, F.M. Hofhuis, B. van Kessel, H. Rozemuller, J.D. de Bruijn, M. de Weers, P.W.H.I. Parren, H.M. Lokhorst, T. Mutis, A.C.M. Martens. Reconstructing the human hematopoietic niche in immune deficient mice, opportunities for studying primary multiple myeloma. **Blood.** 2012; 120(3): e9-e16.

van der Veer, M.S., M de Weers, B van Kessel, J M Bakker, S Wittebol, P W H I Parren, H M Lokhorst and T Mutis The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. **Blood Cancer Journal.** (2011) 1, e41

De Weers, M., Y.-T. Tai, M.S. van der Veer, J.M. Bakker, T. Vink, D.C.H. Jacobs, L.A. Oomen, M. Peipp, T. Valerius, J.W. Slootstra, T. Mutis, W.K. Bleeker, K.C. Anderson, H.M. Lokhorst, J.G.J. van de Winkel, and P.W.H.I. Parren. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, effectively induces killing of multiple myeloma tumor cells. **J. Immunol.** 2011; 186: 1840-1848.

Van der Veer, M.S., M. de Weers, B. van Kessel, J.M. Bakker, S. Wittebol, P.W. Parren, H.M. Lokhorst, T. Mutis. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. **Haematologica.** 2011; 96: 284-90.

DuoBody

Labrijn, A.F. J.I. Meesters, B.E.C.G. de Goeij, E.T.J. van den Bremer, J. Neijssen, M.D. van Kampen, K. Strumane, S. Verploegen, A. Jundu, M.J. Gramer, P.H.C. van Berkel, J.G.J. van de Winkel, J. Schuurman, P.W.H.I. Parren. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. **PNAS.** 2013 Mar 26; 110(13):5145-50.

Schuurman, J., A.F. Labrijn, P.W.H.I. Parren. Fab-arm exchange. What's in a name? **MAbs.** 2012; 4(6):36.

Labrijn, A.F., T. Rispens, J. Meesters, R.J. Rose, T.H. den Bleker, S. Loverix, E.T.J. van den Bremer, J. Neijssen, T. Vink, I. Lasters, R.C. Aalberse, A.J.R. Heck, J.G.J. van de Winkel, J. Schuurman, and P.W.H.I. Parren. Species-specific determinants in the immunoglobulin CH3 domain enable Fab-arm exchange by affecting the non-covalent CH3-CH3 interaction strength. **J. Immunol.** 2011; 187: 3238-3246.

Rose R.J., A.F. Labrijn, E.T.J. van den Bremer, S. Loverix, I. Lasters, P.H.C. van Berkel, J.G.J. van de Winkel, J. Schuurman, P.W.H.I. Parren, and A.J.R. Heck. Quantitative analysis of the interaction strength and dynamics of human IgG4 half-molecules by native mass spectrometry. **Structure** 2011; 19: 1274-1282.

Labrijn A.F., J. Schuurman, J.G.J. van de Winkel, and P.W.H.I. Parren. Reply to Fab Arm exchange (correspondence). **Nature Biotechnol.** 2010; 28: 125-126.

Labrijn, A.F., A. Ortiz Buijsse, E.T.J. van den Bremer, A.Y.W. Verwilligen, W.K. Bleeker, S.J. Thorpe, J. Killestein, C.H. Polman, R.C. Aalberse, J. Schuurman, J.G.J. van de Winkel, and P.W.H.I. Parren. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. **Nature Biotechnol.** 2009; 27: 767-771.

van der Neut Kofschoten, M., J. Schuurman, M. Losen, W.K. Bleeker, P. Martinez-Martinez, E. Vermeulen, T.H. den Bleker, L. Wiegman, T. Vink, L.A. Aarden, M.H. De Baets, J.G.J. van de Winkel, R.C. Aalberse, P.W.H.I. Parren. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. **Science** 2007; 317: 1554-1557.

Pre-Clinical

Engelberts, P.J., C. Badoil, F.J. Beurskens, D. Boulay-Moine, K. Grivel, P.W.H.I. Parren, M. Moulard. A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: Proof of principle with rituximab and ofatumumab. **Journal of Immunological Methods**. 338(2013): 8-17.

Glorius, P. A. Baerenwaldt, C. Kellner, M. Staudinger, M. Dechant, M. Stauch, F.J. Beurskens, P.W.H.I. Parren, J.G.J. van de Winkel, T. Valerius, A. Humpe, R. Repp, M. Gramatzki, F. Nimmerjahn, M. Peipp. the novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells. **Leukemia**. (2013) 27: 190-201.

Rispens, T. J. Meesters, T.H. den Bleker, P. Ooijevaar-De Heer, J. Schuurman, P.W.H.I. Parren, A. Labrijn, R.C. Aalberse. Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer. **Molecular Immunology**. 53 (2013): 35-42.

Rose, R.J., P.H.C. van Berkel, E.T.J. van den Bremer, A.F. Labrijn, T. Vink, J. Schuurman, A.J.R. Heck, P.W.H.I. Parren. Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG. **MAbs** 5:2, 1-10 Mar-Apr 2013.

Ball, C., B. Fox, S. Hufton, G. Sharp, S. Poole, R. Stebbings, D. Eastwood, L. Findlay, P.W.H.I. Parren, R. Thorpe, A. Bristow, S.J. Thorpe. Antibody constant region influences TGN1412-like functional activity *in vitro*. **The Journal of Immunology**. 2012; Nov-12.

Kalay, H., M. Ambrosini, P.H.C. van Berkel, P.W.H.I. Parren, Y. van Kooyk, J.J.G. Vallejo. Online nanoliquid chromatography-mass spectrometry and nanofluorescence detection for high-resolution quantitative N-glycan analysis. **Analytical Biochemistry**. 2012; 423(1): 153-162.

Kellner, C., D. Hallack, P. Glorius, M. Staudinger, S.M. Nodehi, R. Repp, M. de Weers, J.G.J. van de Winkel, P.W.H.I. Parren, A. Humpe, M. Gramatzki and M. Peipp. Fusion proteins between ligands for NKG2D and CD20-directed single chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody dependent cellular cytotoxicity. **Leukemia**. 2012; 26(4): 830-834.

Kellner, C., T. Maurer, D. Hallack, R. Repp, J.G.J. van de Winkel, P.W.H.I. Parren, T. Valerius, A. Humpe, M. Gramatzki and M. Peipp. Mimicking An Induced Self Phenotype by Coating Lymphomas with the Nkp30-Ligand B7-H6 Promotes NK Cell Cytotoxicity. **The Journal of Immunology**. 2012; 189(10): 5037-5046.

Lohse, S., C. Brunke, S. Derer, M. Peipp, P. Boross, C. Kellner, T. Beyer, M. Dechant, J.G.J. van de Winkel, J.H.W. Leusen, T. Valerius. Characterisation of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. **Journal of Biological Chemistry**. 2012; 287(30): 25139-25150.

Moldt, B., M. Shibata-Koyama, E. Rakasz, N. Schultz, Y. Kanda, D. Dunlop, S. Finstad, C. Jin, G. Landucci, M. Alpert, A.S. Dugast, P. Parren, F. Nimmerjahn, D. Evans, G. Alter, D. Forthal, J. Schmitz, S. Iida, P. Poignord, D. Watkins, A. Hessel, D. Burton. A non-fucosylated variant of the anti-HIV-1 MAb b12 has enhanced FcγRIIIa-mediated antiviral activity *in vitro* but not improved protection against mucosal SHIV challenge in macaques. **Journal of Virology**. 2012; 86(11): 6189-6196.

Otten, M.A., J.E. Bakema, C.W. Tuk, M.J. Glennie, A.L. Tutt, R.H. Beelen, J.G. van de Winkel and M. van Egmond. Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells. **European Journal of Immunology**. 2012; 42(7): 1815-1821.

Overdijk, M.B., S. Verploegen, W.K. Bleeker, P.W.H.I. Parren. Role of IgG Fc Receptors in Monoclonal Antibody Therapy of Cancer. IgG Fc: Linking Adaptive and Innate Immunity. M.E. Ackerman and F. Nimmerjan eds. Elsevier, Amsterdam.

Overdijk, M.B., S. Verploegen, A.O. Buijsse, T. Vink, J.H.W. Leusen, W.K. Bleeker, P.W.H.I. Parren. Cross-talk between human IgG isotypes and murine effector cells. **The Journal of Immunology**. 2012; 189(7): 3430-3438.

Pre-Clinical Continued

- Peipp, M., J.G.J. van de Winkel, and T. Valerius. Molecular engineering to improve antibodies' anti-lymphoma activity. **Best Pract. Res. Clin. Haematol.** 2011; 24: 217-229.
- Gramer, M.J., J.J. Eckblad, R. Donahue, J. Brown, K. Vickerman, P. Priem, E.T. van den Bremer, J. Gerritsen, and P.H. van Berkel. Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose. **Biotechnol. Bioeng.** 2011; 108: 1591-1602.
- Gerritsen, A.F., M. Bosch, M. de Weers, J.G.J. van de Winkel, and P.W.H.I. Parren. High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging. **J. Immunol. Methods** 2010; 352: 140-146.
- Van Meerten, T., H. Rozemuller, S. Hol, P. Moerer, M. Zwart, A. Hagenbeek, W.J.M. Mackus, P.W.H.I. Parren, J.G.J. van de Winkel, S.B. Ebeling, and A.C.M. Martens. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist Rituximab mediated lysis. **Haematologica** 2010; 95: 2063-2071 [Epub ahead of print].
- Van Berkel, P.H.C., J. Gerritsen, E. van Voskuilen, G. Perdok, T. Vink, J.G.J. van de Winkel, and P.W.H.I. Parren. Rapid production of recombinant human IgG with improved ADCC effector function in a transient expression system. **Biotechnol. Bioeng.** 2009; 105: 350-357.
- Van Berkel, P.H.C., J. Gerritsen, G. Perdok, J. Valbjørn, T. Vink, J.G.J. van de Winkel, and P.W.H.I. Parren. N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. **Biotechnol. Prog.** 2009; 25: 244-251.
- Raaz D., M. Herrmann, A.B. Ekici, L. Klinghammer, B. Lausen, R.E. Voll, J.H.W. Leusen, J.G.J. van de Winkel, W.G. Daniel, A. Reis, C.D. Garlich. FcγRIIa genotype is associated with acute coronary syndromes as first manifestation of coronary artery disease. **J. Atherosclerosis** 2009; 205: 512-516.
- Ruuls, S., J.J. Lammerts van Bueren, J.G.J. van de Winkel, and P.W.H.I. Parren. Novel human antibody therapeutics: the age of the Umabs. **Biotechnol. J.** 2008; 3: 1157-1171.
- Otten, M.A., G.J. van der Bij, S.J. Verbeek, E. Rudolph, F. Nimmerjahn, J.V. Ravetch, R.H.J. Beelen, J.G.J. van de Winkel, and M. van Egmond. Experimental antibody therapy of liver metastases reveals functional redundancy between FcγRI and FcγRIV. **J. Immunol.** 2008; 181: 6829-6836.
- Parren, P.W.H.I., and J.G.J. van de Winkel. An integrated science-based approach to drug development. **Curr. Opin. Immunol.** 2008; 20:426-430.
- Aarden, L., S.R. Ruuls, and G. Wolbink. Immunogenicity of anti-tumor necrosis factor antibodies - toward improved methods of anti-antibody measurement. **Curr. Opin. Immunol.** 2008; 20:431-235.
- Labrijn, A.F., R.C. Aalberse, and J. Schuurman. When binding is enough: nonactivating antibody formats. **Curr. Opin. Immunol.** 2008; 20:479-485.
- Skov, L., F.J. Beurskens, C.O.C. Zachariae, S. Reitamo, J. Teeling, D. Satijn, K.M. Knudsen, E.P.J. Boot, D. Hudson, O. Baadsgaard, P.W.H.I. Parren, and J.G.J. van de Winkel. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in Palmoplantar Pustulosis. **J. Immunol.** 2008; 181: 669-679.
- Beekman, J.M., C.E. van der Poel, J.A. van der Linden, D.L.C. van den Berg, P.V.E. van den Berghe, J.G.J. van de Winkel, and J.H.W. Leusen. Filamin A stabilizes FcγRI surface expression and prevents its lysosomal routing. **J. Immunol.** 2008, 180: 3938-3945.
- McIntosh, R.S., J. Shi, R.M. Jennings, J.C. Chappel, T.F. de Koning-Ward, T. Smith, J. Green, M. van Egmond, J.H.W. Leusen, M. Lazarou, J.G.J. van de Winkel, T.S. Jones, B.S. Crabb, A.A. Holder, and R.J. Pleass. The importance of human FcγRI in mediating protection to malaria. **PLoS Pathogens** 2007; 3: e72.

- Dechant, M., T. Beyer, T. Schneider-Merck, W. Weisner, M. Peipp, J.G.J. van de Winkel, and T. Valerius. Effector mechanisms of recombinant IgA antibodies against Epidermal Growth Factor Receptor. **J. Immunol.** 2007; 179: 2936-2943.
- Otten, M.A., J.H.W. Leusen, E. Rudolph, J.A. van der Linden, R.H.J. Beelen, J.G.J. van de Winkel, and M. van Egmond. FcR γ chain dependent signaling in immature neutrophils is mediated by Fc α RI, but not by Fc γ RI. **J. Immunol.** 2007; 179: 2918-2924.
- Hessell, A.J., L. Hangartner, M. Hunter, C.E.G. Havenith, F.J. Beurskens, J.M. Bakker, C.M.S. Lanigan, G. Landucci, D.N. Forthal, P.W.H.I. Parren, P.A. Marx, and D.R. Burton. Fc receptor but not complement binding is important in antibody protection against HIV. **Nature** 2007; 449: 101-104.
- Bakema, J.E., S. De Haij, C.F. den Hartog-Jager, J. Bakker, G. Vidarsson, M. Van Egmond, J.G.J. van de Winkel, and J.H.W. Leusen. Signaling through mutants of the IgA receptor, CD89, and consequences for FcR γ -chain interaction. **J Immunol.** 2006; 176: 3603-3610.
- Rodriguez, M.E., S.M.M. Hellwig, M.L.A. Perez Vidakovics, G.A.M. Berbers, and J.G.J. van de Winkel. Bordetella pertussis attachment to respiratory epithelial cells can be impaired by Fimbriae-specific antibodies. **FEMS Immunol. Med. Microbiol.** 2006; 46: 39-47.
- Vidarsson, G., A.M. Stemerding, F.E.M. Rebers, M. de Haas, and J.G.J. van de Winkel. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. **Blood** 2006; 108: 3573-3579.
- Bevaart, L., J. Goldstein, L. Vitale, C. Russoniello, J. Trembl, J. Zhang, R.F. Graziano, J.H.W. Leusen, J.G.J. van de Winkel, and T. Keler. Direct targeting of genetically modified tumour cells to Fc γ RI triggers potent tumor cytotoxicity. **Brit. J. Haematol.** 2006; 132: 317-325.
- Bevaart, L., M.J.H. Jansen, M.J. van Vugt, J.S. Verbeek, J.H.W. Leusen, and J.G.J. van de Winkel. The high-affinity IgG receptor, Fc γ RI, plays a central role in antibody therapy of experimental melanoma. **Cancer Res.** 2006; 66: 1261-1264.
- Van Vuuren, A.J., J. van Roon, V. Walraven, I. Stuij, M.C. Harmsen, J.G.J. van de Winkel, and T. Thepen. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model. **J. Immunol.** 2006; 176: 5833-5838.
- Steeghs, L., S.J. van Vliet, H. Uronen-Hansson, A. van Mourik, A. Engering, M. Sanchez-Hernandez, N. Klein, R. Callard, J.P.M. van Putten, P. van der Ley, Y. van Kooyk, and J.G.J. van de Winkel. Neisseria meningitidis expressing IgtB lipopolysaccharide targets DC-SIGN and modulates dendritic cell function. **Cell. Microbiol.** 2006; 8: 316-325.
- Van Royen, A., E.A.M. Sanders, V. Walraven, M. Voorhorst, E. Saeland, J.L. Teeling, A. Gerritsen, M.A. van dijk, W. Kuis, G.T. Rijkers, L. Vitale, T. Keler, S.E. McKenzie, J.H.W. Leusen, and J.G.J. van de Winkel. Novel human CD32 mAb blocks experimental immune hemolytic anemia in Fc γ RIIA transgenic mice. **Brit. J. Haematol.** 2005; 130: 130-137.
- Vidarsson, G., N. Overbeeke, A.M. Stemerding, G. van den Dobbelen, P. van Ulsen, P. van der Ley, M. Kilian, and J.G.J. van de Winkel. Working mechanism of IgA1-protease: cleavage of IgA1 antibody to PorA of Neisseria meningitidis requires de novo synthesis of IgA1-protease. **Infect. Immunity** 2005; 73: 6721-6726.
- Bevaart, L., H.H. van Ojik, A.W. Sun, T.H. Sulahain, J.H.W. Leusen, G.J. Weiner, J.G.J. van de Winkel and M.J. van Vugt. CpG oligodeoxynucleotides enhance Fc γ RI-mediated cross presentation by dendritic cells. **Int. Immunol.** 2004; 16 : 1091-1098.
- Beekman, J.M., J. van der Linden, J. Bakema, B. Tops, M. Hinten, M.J. van Vugt, J.G.J. van de Winkel and J.H.W. Leusen. Modulation of Fc γ RI (CD64) ligand binding by blocking peptides of periplakin. **J. Biol. Chem.** 2004; 279 : 33875-33881.
- Beekman, J.M., J. Bakema, J.H.W. Leusen and J.G.J. van de Winkel. Direct interaction between Fc γ RI (CD64) and periplakin controls receptor endocytosis and ligand binding capacity. **Proc. Natl. Acad. Sci. USA** 2004; 101 : 10392-10397.
- Villadsen, L.S., L. Skov and O. Baadsgaard. Biological response modifiers and their potential use in the treatment of inflammatory skin diseases. **Exp. Dermatol.** 2003; 12 : 1-10.

Pre-Clinical Continued

Van Ojik, H.H., L. Bevaart, C.E. Dahle, A. Bakker, M.J. Jansen, M.J. van Vugt, J.G.J. van de Winkel and G.J. Weiner. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. **Cancer Res.** 2003; 63 : 5595-600.

Parren, P.W.H.I., J.H.W. Leusen and J.G.J. van de Winkel. Antibody-catalyzed water oxidation: state-of-the-art immunity or ancient history? **Trends Immunol.** 2003; 24 : 467-9.

Hellwig, S.M.M., M.E. Rodriguez, G.A. Berbers, J.G.J. van de Winkel and F.R. Mooi. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. **J. Infect. Dis.** 2003; 188 : 738-42.

Saeland, E., G. Vidarsson, J.H.W. Leusen, E. van Garderen, M.H. Nahm, H. Vile-Weekhout, V. Walraven, A.M. Stemerding, J.S. Verbeek, G.T. Rijkers, W. Kuis, E.A.M. Sanders and J.G.J. van de Winkel. Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice. **J. Immunol.** 2003; 170 : 6158-64.

Saeland, E., J.H.W. Leusen, G. Vidarsson, W. Kuis, E.A.M. Sanders, I. Jonsdottir and J.G.J. van de Winkel. Role of Fcγ receptors in vaccine induced immunity to Streptococcus pneumoniae. **J. Infect. Dis.** 2003; 187 : 1686-93.

Stassen, M.H., F. Meng, E. Melgert, B.M. Machiels, S.H. Im, S. Fuchs, A.F. Gerritsen, M.A. van Dijk, J.G.J. van de Winkel and M.H. de Baets. Experimental autoimmune myasthenia gravis in mice expressing human immunoglobulin loci. **J. Neuroimmunol.** 2003; 135 : 56-61.

Monteiro, R.C. and J.G.J. van de Winkel. IgA Fc receptors. **Annu. Rev. Immunol.** 2003; 177-204.

Van Spriël, A.B., H.H. van Ojik, A. Bakker, M.J.H. Jansen and J.G.J. van de Winkel. Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. **Blood** 2003; 101 : 253-258.

Glennie, M.J. and J.G.J. van de Winkel. Renaissance of cancer therapeutic antibodies. **Drug Discov. Today** 2003; 8 : 503-510

Dechant, M., G. Vidarsson, B. Stockmeyer, R. Repp, M.J. Glennie, M. Gramatzki, J.G.J. van de Winkel and T. Valerius. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. **Blood** 2002; 100 : 4574-4580.

Ioan-Facsinay, A., S.J. de Kimpe, S.M.M. Hellwig, P.L. van Lent, F.M.A. Hofhuis, H.H. van Ojik, C. Sedlik, S.A. da Silveira, J. Gerber, Y.F. de Jong, R. Roozendaal, L.A. Aarden, W.B. van den Berg, T. Saito, D. Mosser, S. Amigorena, C. Izui, G-J.B. van Ommen, M. van Vugt, J.G.J. van de Winkel and J.S. Verbeek. FcγRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses and protection from bacterial infection. **Immunity** 2002; 16 : 391-402.

Zalutumumab

Derer, S., S. Berger, M. Schlaeth, T. Schneider-Merck, K. Klausz, S. Lohse, M.B. Overdijk, M. Dechant, C. Kellner, I. Nagelmeijer, A. H. Scheel, J.J. Lammerts van Bueren, J.G.J. van de Winkel, P.W.H.I. Parren, M. Peipp, T. Valerius. Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression. **Neoplasia.** 2012; 14(3): 190-205.

Lammerts van Bueren, J.J., T. Rispens, S. Verploegen, T. van der Palen-Merkus, A.L. Turinsky, S. Stapel, L.J. Workman. H. James, P.H.C. van Berkel, J.G.J. van de Winkel, T.A.E. Platts-Mills, and P.W.H.I. Parren. Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains. **Nature Biotechnol.** 2011; 29: 574-576.

Overdijk M.B., S. Verploegen, J.H. van den Brakel, J.J. Lammerts van Bueren, T. Vink, J.G.J. van de Winkel, P.W.H.I. Parren, and W.K. Bleeker. EGFR antibody induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting metastasis and tumorigenesis even of mutated KRAS tumor cells. **J. Immunol.** 2011; 187: 3383-3390.

Klausz, K., S. Berger, J.J. Lammerts van Bueren, S. Derer, S. Lohse, M. Dechant, J.G.J. van de Winkel, M. Peipp, P.W.H.I. Parren, and T. Valerius. Complement-mediated tumor-specific cell lysis by antibody combinations targeting the epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). **Cancer Sci.** 2011; 102: 1761-1768.

Zalutumumab Continued

Machiels, J.P., S. Subramanian, A. Ruzsa, G. Repassy, I. Lifirenko, A. Flygare, P. Sorensen, T. Nielsen, S. Lisby, and P.M. Clement. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. **Lancet Oncol.** 2011; 12: 333-343.

Schneider-Merck, T., J.J. Lammerts van Bueren, S. Berger, K. Rossen, P.H.C. van Berkel, S. Derer, T. Beyer, S. Lohse, W.K. Bleeker, M. Peipp, P.W.H.I. Parren, J.G.J. van de Winkel, T. Valerius, and M. Dechant. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. **J. Immunol.** 2010; 184: 512-520.

Dechant, M., W. Weisner, S. Berger, M. Peipp, T. Beyer, T. Schneider-Merck, J.J. Lammerts van Bueren, W.K. Bleeker, P.W.H.I. Parren, J.G.J. van de Winkel, and T. Valerius. Complement-dependent tumor cell lysis triggered by combinations of Epidermal Growth Factor receptor antibodies. **Cancer Research** 2008; 68: 4998-5003.

Peipp, M., T. Schneider-Merck, M. Dechant, T. Beyer, J.J. Lammerts van Bueren, W.K. Bleeker, P.W.H.I. Parren, J.G.J. van de Winkel, and T. Valerius. Tumor cell killing mechanisms of EGF-R antibodies are not affected by lung cancer-associated EGF-R kinase mutations. **J. Immunol.** 2008; 180: 4338-4345.

Lammerts van Bueren, J.J., W.K. Bleeker, H.O. Bøgh, M. Houtkamp, J. Schuurman, J.G.J. van de Winkel, and P.W.H.I. Parren. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. **Cancer Res.** 2006; 66: 7630-7638.

Bleeker, W.K., J.J. Lammerts van Bueren, H.H. van Ojik, A.F. Gerritsen, M. Pluyter, M. Houtkamp, E. Halk, J. Goldstein, J. Schuurman, M.A. van Dijk, J.G.J. van de Winkel and P.W.H.I. Parren. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. **J. Immunol.** 2004; 173 : 4699-4707.

Zanolimumab

d'Amore, F., J. Radford, T. Relander, M. Jerkeman, H. Tilly, A. Osterborg, F. Morschhauser, M. Gramatzki, M. Dreyling, B. Bang, and H. Hagberg. Phase II trial of Zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. **Br. J. Haematol.** 2010; 150: 565-573.

Rider, D.A., C.E.G. Havenith, R. de Ridder, J. Schuurman, C. Favre, J.C. Cooper, S. Walker, O. Baadsgaard, S. Marschner, J.G.J. van de Winkel, J. Cambier, P.W.H.I. Parren, and D.R. Alexander. A human CD4 monoclonal antibody for the treatment of T cell lymphoma combines inhibition of T cell signaling by a dual mechanism with potent Fc-dependent effector activity. **Cancer Res.** 2007; 67: 9945-53.

Kim, Y.H., M. Duvic, E. Obitz, R. Gniadecki, L. Iversen, A. Osterborg, S. Whittaker, T.M. Illidge, T. Schwarz, R. Kaufmann, K. Cooper, K.M. Knudsen, S. Lisby, O. Baadsgaard, and S.J. Knox. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. **Blood** 2007; 109: 4655-4662.

Villadsen, L.S., L. Skov, T.N. Dam, F. Dagnaes-Hansen, J. Rygaard, J. Schuurman, P.W.H.I. Parren, J.G.J. van de Winkel, and O. Baadsgaard. In situ depletion of CD4+ cells in human skin by Zanolimumab. **Arch. Dermatol. Res.** 2007; 298: 449-455.

Skov, L., K. Kragballe, C. Zachariae, E.R. Obitz, E.A. Holm, G.B. Jemec, H. Solvsten, H.H. Ibsen, L. Knudsen, P. Jensen, J.H. Petersen, T. Menne and O. Baadsgaard. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. **Arch. Dermatol.** 2003; 139 : 1433-9.

Other

Parren, W.H.I. and A. Lugovskoy. A review of "Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry" by William R. Strohl and Lila M. Strohl. **MAbs.** 5:2: 1-3; 2013.

van Schouwenburg, P.A., L.A. van de Stadt, R.N. de Jong, E.E.L. van Buren, S. Kruithof, E. de Groot, M. Hart, S.M. van Ham, T. Rispens, L. Aarden, G.J. Wolbink, D. Wouters. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. **Annals of the Rheumatic Diseases.** 2013; 72: 104-109.

Bangsgaard, N., M. Houtkamp, D.H. Schuurhuis, P.W.H.I. Parren, O. Baadsgaard, H.W.M. Niessen, L. Skov. Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor; a proof-of-principle study in human volunteers. **PLoS ONE**. June-2012, e39706.

Raaz-Schrauder, D., A.B. Ekici, L.E. Munoz, L. Klinghammer, R.E. Voll, J.H. Leusen, J.G. van de Winkel, A. Reis, G. Schett, C.D. Garlachs, M. Hermann. Patients with unstable angina pectoris show an increased frequency of the Fc gamma RIIa R131 allele. **Autoimmunity**. 2012; 45(7): 556-564.

Seshasayee, D. W.P. Lee, M. Zhou, J. Shu, E. Suto, J. Zhang, L. Diehl, C.D. Austin, Y.G. Meng, M. Tan, S.L. Bullens, S. Seeber, M.E. Fuentes, A.F. Labrijn, Y.M.F. Graus, L.A. Miller, E.S. Schelegle, D.M. Hyde, L.C. Wu, S.G. Hymowitz, and F. Martin. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. **J. Clin. Invest**. 2007; 117: 3868-3878.

Baslund, B., N. Tvede, B. Danneskiold-Samsoe, P. Larsson, G. Panayi, J. Petersen, L.J. Petersen, F. Beurskens, J. Schuurman, J.G.J. van de Winkel, P.W.H.I. Parren, J. A. Gracie, S. Jongbloed, F.Y. Liew, and I.B. McInnes. Targeting interleukin-15 in patients with rheumatoid arthritis (RA): a proof-of-concept study. **Arthritis Rheum**. 2005; 52: 2686-2692.

Villadsen, L.S., J. Schuurman, F. Beurskens, T.N. Dam, F. Dagnæs-Hansen, L. Skov, J. Rygaard, M.M. Voorhorst-Ogink, A.F. Gerritsen, M.A. van Dijk, P.W.H.I. Parren, O. Baadsgaard and J.G.J. van de Winkel. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. **J. Clin. Invest**. 2003; 112 : 1571-1580.